Market Overview

UPDATE: Morgan Stanley Initiates Infinity Pharmaceuticals at Overweight on Blood Cancer Drug Data

Share:
Related INFI
JPM Securities Picks Through Biotech News For Winners
UPDATE: Infinity Pharmaceuticals Posts Q4 Loss

Morgan Stanley initiated Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $47.00 price target.

Morgan Stanley noted, "Infinity's wholly-owned early stage IPI-145 for blood cancers has shown positive early data and is on track to figure significantly in an emerging BCR drug class with multi-billion dollar potential. 2013 holds multiple catalysts to further validate IPI-145's efficacy/safety."

Infinity Pharmaceuticals closed at $35.20 on Friday.

Latest Ratings for INFI

DateFirmActionFromTo
Jan 2015Morgan StanleyDowngradesOverweightEqualweight
Dec 2014Credit SuisseUpgradesNeutralOutperform
Nov 2014NomuraMaintainsNeutral

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...